http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011200533-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8f3fc0bcee25a1161415431ccb1faf7 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
filingDate | 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a09c23ea1623ed803daabdd5a321950 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ec9c89d0c0e1abe8fb31fae1584d4cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df66918ea8747c97423907e23ed46667 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dd5c01df2df637d6c0f8fbea5cf7b47 |
publicationDate | 2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2011200533-A1 |
titleOfInvention | Compounds for the diagnosis of diseases associated with vcam expression |
abstract | The present invention relates to a compound of the following general formula (I): n Signal-Linker-Peptide (I) in which: -Signal represents a signal entity; -Linker, which may or may not be present, represents a chemical bond, and -Peptide represents a peptide comprising a VCAM-targeting peptide, the VCAM-targeting peptide being chosen from the peptides of formula below and the functional equivalents thereof:n a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (SEQ ID No. 1) where X1 is absent or chosen from cysteine and methionine; X2 chosen from asparagine and glutamine; X3 chosen from asparagine and glutamine; X4 chosen from serine and threonine; X5 chosen from lysine, arginine, histidine and ornithine; X6 chosen from serine and threonine; X7 chosen from histidine, arginine and lysine; X8 chosen from threonine and serine; X9 is absent or chosen from cysteine and methionine; preferably, the peptide CNNSKSHTC (SEQ ID No. 2) and the peptide NNSKSHT (SEQ ID No. 3);n b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (SEQ ID No. 4) with X10 chosen from cysteine and methionine; X11 chosen from methionine and cysteine; X12 chosen from lysine, arginine and alanine; X13 chosen from threonine and serine; X14 chosen from aspartic acid and glutamic acid; X15 chosen from threonine and serine; X16 chosen from arginine, alanine and lysine; X17 chosen from leucine, isoleucine and valine; X18 chosen from cysteine and methionine; preferably, the peptide CMKTDTRLC (SEQ ID No. 5); and the pharmaceutically acceptable salts of these compounds of a) or of b). |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771423-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015064115-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11123316-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10653649-B2 |
priorityDate | 2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 523.